Strategic partnerships Strong collaboration potential with Abbott to co-develop next-generation extravascular ICD systems and EV-ICD technology, creating joint sales opportunities and accelerated market access.

Clinical expansion Advancing EV-ICD and temporary pacing solutions positions AtaCor to target hospitals and trauma centers seeking less invasive, imaging-free pacing options with potentially lower complication rates.

Financing momentum Recent multi-million dollar funding rounds and pivotal U.S. studies signal investor validation and resources to scale clinical evidence, enabling sales teams to leverage proven outcomes for payer discussions.

Market readiness Despite not yet commercial, the ongoing trials and collaborations create a pre-launch window to engage key KOLs, hospital procurement, and distributors ahead of anticipated approvals.

Competitive positioning Unique value proposition focused on extravascular pacing and defibrillation options offers a differentiator from traditional transvenous systems, enabling targeted outreach to centers pursuing innovation in cardiac rhythm management.